摘要
目的探讨中晚期非小细胞肺癌患者采用DC-CIK免疫细胞治疗联合顺铂化疗对外周血淋巴细胞和细胞因子变化的影响。方法选取2020年1月-2021年12月在甘肃省武威肿瘤医院收治的105例中晚期非小细胞肺癌患者作为研究对象。观察组70例给予DC-CIK免疫细胞治疗联合顺铂化疗,对照组35例仅给予顺铂化疗。比较两组外周血淋巴细胞、细胞因子变化以及临床疗效。结果观察组临床总有效率为52.85%(37/70),显著高于对照组的31.42%(11/35),差异有统计学意义(P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组(t=3.665、5.827、2.942,P均<0.05);CD8^(+)、γ干扰素、肿瘤坏死因子-α、白介素-10、白介素-6水平均低于对照组(t=3.932、3.889、3.753、6.815、9.169,P均<0.05),差异有统计学意义。观察组总体改善率为87.14%(61/70),显著高于对照组的68.57%(24/35),差异有统计学意义(χ^(2)=4.317,P<0.05)。观察组不良反应发生率为27.14%(19/70),显著低于对照组的48.57%(17/35),差异有统计学意义(χ^(2)=4.755,P<0.05)。结论DC-CIK免疫细胞治疗联合顺铂化疗对中晚期非小细胞肺癌患者的效果显著,可提高免疫功能和生存质量,且安全性高。
Objective To investigate the effect of DC-CIK immune cell therapy combined with cisplatin chemotherapy on the changes of peripheral blood lymphocytes and cytokines in patients with advanced non-small cell lung cancer.Methods A total of 105 patients with advanced non-small cell lung cancer who were admitted to Wuwei Cancer Hospital in Gansu Province from January 2020 to December 2021 were selected as the research objects.70 patients in the observation group were treated with DC-CIK immune cell therapy combined with cisplatin chemotherapy,and 35 patients in the control group were treated with cisplatin chemotherapy.The changes in peripheral blood lymphocytes,cytokines and clinical efficacy were compared.Results The total clinical effective rate of the observation group was 52.85%,which was significantly higher than that of the control group(31.42%)(P<0.05).After treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the observation group were significantly higher than those in the control group(t=3.665,5.827,2.942,all P<0.05).The levels of CD8,interferon-γ,tumor necrosis factor-α,IL-10 and IL-6 were significantly lower than those in the control group(t=3.932,3.889,3.753,6.815,9.169,all P<0.05).The overall improvement rate of the observation group was significantly higher than that of the control group(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than 48.57%in the control group(P<0.05).Conclusion s DC-CIK immune cell therapy combined with cisplatin chemotherapy had a significant effect on patients with advanced non-small cell lung cancer.It could improve immune function,quality of life,and had high safety.
作者
肖永平
潘钰娇
陶文学
陈威佐
王帆
任晓雯
XIAO Yong⁃ping;PAN Yu⁃jiao;TAO Wen⁃xue;CHEN Wei⁃zuo;WANG Fan;REN Xiao⁃wen(Biological Immunotherapy Room,Gansu Wuwei Tumour Hospital,Wuwei,Gansu 733000,China;不详)
出处
《热带医学杂志》
CAS
2022年第7期979-982,共4页
Journal of Tropical Medicine
基金
武威市市列科技计划项目(ww2002069)
作者简介
肖永平(1983-),男,主管检验师,从事生物免疫治疗研究,E⁃mail:xayp456@163.com
